--- title: "Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $48.00 at UBS Group" type: "News" locale: "en" url: "https://longbridge.com/en/news/298066985.md" description: "UBS Group raised its price target for Teva Pharmaceutical Industries (NYSE:TEVA) from $42.00 to $48.00, assigning a 'buy' rating. This follows similar adjustments by other analysts, including Piper Sandler and Barclays. The stock currently holds a consensus 'Moderate Buy' rating with an average target of $42.89. Recent insider selling by EVP Eliyahu Kalif and increased institutional holdings by hedge funds like Legal & General and TD Asset Management were also noted." datetime: "2026-09-04T18:42:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298066985.md) - [en](https://longbridge.com/en/news/298066985.md) - [zh-HK](https://longbridge.com/zh-HK/news/298066985.md) generator: "portal-rs" --- # Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $48.00 at UBS Group Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price target lifted by research analysts at UBS Group from $42.00 to $48.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's target price points to a potential upside of 31.62% from the company's previous close. - MarketBeat Week in Review – 02/03 - 02/07 Other analysts have also recently issued reports about the company. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 28th. Wall Street Zen cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Weiss Ratings raised Teva Pharmaceutical Industries from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, August 21st. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus target price of $42.89. **Check Out Our Latest Research Report on TEVA** ## Teva Pharmaceutical Industries Stock Down 0.4% - Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now TEVA traded down $0.15 on Friday, hitting $36.47. The company had a trading volume of 1,320,011 shares, compared to its average volume of 6,959,974. Teva Pharmaceutical Industries has a 52-week low of $18.21 and a 52-week high of $38.37. The stock has a fifty day simple moving average of $34.58 and a 200-day simple moving average of $33.26. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The firm has a market capitalization of $42.50 billion, a P/E ratio of 60.76, a P/E/G ratio of 4.94 and a beta of 0.87. Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, equities analysts expect that Teva Pharmaceutical Industries will post 1.96 EPS for the current fiscal year. ## Insider Buying and Selling - 2 Generic Drug Stocks Ready to Surge in 2025 In related news, EVP Eliyahu Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the sale, the executive vice president owned 65,621 shares of the company's stock, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.54% of the company's stock. ## Hedge Funds Weigh In On Teva Pharmaceutical Industries Hedge funds have recently modified their holdings of the business. Legal & General Group Plc boosted its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company's stock valued at $112,618,000 after acquiring an additional 228,189 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Teva Pharmaceutical Industries by 8.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company's stock worth $33,506,000 after purchasing an additional 80,106 shares during the period. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $1,098,060,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $9,126,000. Finally, TD Asset Management Inc grew its holdings in Teva Pharmaceutical Industries by 47.1% during the fourth quarter. TD Asset Management Inc now owns 369,023 shares of the company's stock worth $11,517,000 after acquiring an additional 118,075 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors. ## Teva Pharmaceutical Industries Company Profile (Get Free Report) Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries. Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease. ## Read More - Five stocks we like better than Teva Pharmaceutical Industries - Revolution Medicines Got Its Breakthrough—What Moves It Next? - Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy - FB Financial's Southern Expansion and Buybacks Drive Analyst Optimism - AST SpaceMobile Stock Soared 12%—This Was the Catalyst *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now? Before you consider Teva Pharmaceutical Industries, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list. While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md) - [TD.US](https://longbridge.com/en/quote/TD.US.md) - [LGEN.UK](https://longbridge.com/en/quote/LGEN.UK.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [MUFG.US](https://longbridge.com/en/quote/MUFG.US.md) - [8306.JP](https://longbridge.com/en/quote/8306.JP.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) ## Related News & Research - [Teva, Trump Administration Announce Intent To Reach Agreement On Affordable Medicines](https://longbridge.com/en/news/297556815.md) - [J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential](https://longbridge.com/en/news/297923035.md) - [Teva Advances NYSE Listing With ADS Exchange Plan](https://longbridge.com/en/news/297965389.md) - [Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study](https://longbridge.com/en/news/297800772.md) - [Teva, Trump administration pursue Medicaid drug pricing agreement under GENEROUS framework](https://longbridge.com/en/news/297556474.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**